Abstract: Objective: To explore the feasibility of BAG-1 and MCM2 as effective predictors for neoadjuvant chemotherapy (NACT) of cervical cancer. Methods: Clinical data of 90 patients of cervical cancer treated with preoperative platinum-based NACT and surgery were collected in Gansu Provincial Cancer Hospital from January 2015 to June 2018. Immunohistochemical methods were used to detect the expression of BAG-1 and MCM2 proteins in normal cervical tissues and cervical biopsy tissues of the same cervical cancer patients before NACT and after NACT. The expression differences between normal cervical tissues and cervical cancer tissues, cervical cancer tissues before and after NACT was compared, and the correlation of the 2 proteins with the clinical efficacy of NACT was analyzed. Results: The high expression rates of BAG-1 and MCM2 in pre-NACT cervical cancer tissues were 67.8% (61/90) and 81.1% (73/90), respectively, which was higher than 11.7% (7/60) and 6.7% (4/60) of normal cervical tissues. There was a significant difference between the two groups ( χ2=45.736 and 76.909，both P=0.000). The high expression rates of BAG-1 and MCM2 in cervical cancer tissues after NACT were 70.0% (63/90) and 78.9% (71/90), respectively. There was no significant difference between before and after NACT( χ2=0.104 and 0.139, both P＞0.05). After NACT, 59 of 90 cases of cervical cancer were effective (65.6%), while 31 of 90 cases were invalid (34.4%). There was no correlation of the efficacy of NACT with age, pathological type, differentiation degree, tumor maximum diameter and FIGO stage (both P＞0.05). The high expression rate of BAG-1 in the chemotherapy-effective group was lower than that ineffective group, and there was a significant difference between the two groups (54.2% vs. 93.5%, χ2=12.636, P=0.000). However, there was no significant difference of MCM2 high expression rate between the effective group and the ineffective group（79.7% vs. 83.9%, χ2=0.235, P=0.628）. Conclusions: Detection of BAG-1 expression may be a reference indicator for predicting the chemotherapy efficacy of platinum-based NACT regimens for cervical cancer.

Key words: Uterine cervical neoplasms;, BAG-1;, MCM2, Immunohistochemistry;, Neoadjuvant chemotherapy;, Treatment outcome